Recent Updates
Recently added Catalysts

Itopride

Phase 3

Functional Dyspepsia | Small molecule | Gastrointestinal |Abbott Laboratories|Last Updated: Apr 3, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment564

FDA Designations

No designations recorded

Clinical trial landscape

Itopride · 1 trial · 1 indication

Phase 3 1
NCT06217393Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional DyspepsiaFunctional Dyspepsia
COMPLETED564 Analytics
PHASE3COMPLETED
Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
Functional DyspepsiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Change in the Overall Severity of Functional Dyspepsia Between Baseline and Week 8, as Measured by the LDQ Severity Score
8 weeks

Change in the overall severity of functional dyspepsia between baseline and week 8, as measured by the Leeds Dyspepsia Questionnaire (LDQ) severity score consisting of 15 questions, where questions 1-8 are used to measure the severity, on a scale of 0 to 5 (0= absence, 1= very mild, 5=very severe). End Result: Maximum severity score is 40, symptom free=0, very mild =1-4, mild=5-8, moderate=9-15, severe is 16-40

Secondary Endpoints

Change in the Overall Severity of Functional Dyspepsia Between Baseline and Week 4, as Measured by the LDQ Severity Score
4 weeks
Disease Specific Quality of Life (Nepean Dyspepsia Index NDI) Assessed at Baseline and Week 8 in Terms of Change in % of Functional Ability.
8 weeks
Change From Baseline of NRS 11 Score for Symptoms (Sensation of Bloating) After 4 Weeks of Treatment.
4 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main mealsEXPERIMENTALTest group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)
Active Control group - Itopride Hydrochloride 50 mg filmACTIVE_COMPARATOR -

Interventions

NameTypeDescription
Itopride Hydrochloride 150 mg extended release tabletsDRUGThe intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment) • Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals
Itopride Hydrochloride 50 mg film coated tabletsDRUGThe intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment) • Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 99 Years
SexALL
Healthy VolunteersNo
Study Sites19

Inclusion Criteria: 1. Adult male and/or non-pregnant non-lactating female subjects aged above 18 years. 2. Subjects provided written informed consent and are willing to participate in the study. 3. Subjects with functional (non-ulcer) dyspepsia according to Rome IV criteria including postprandial ...

Countries:ArmeniaMalaysiaPhilippinesThailandVietnam
Unlock Eligibility Criteria